Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2018, Article ID 5356245, 7 pages
https://doi.org/10.1155/2018/5356245
Research Article

Frequency of Red Blood Cell Alloimmunization in Patients with Sickle Cell Disease in Palestine

1Department of Medical Technology, Faculty of Allied Health Sciences, Arab American University in Jenin, State of Palestine
2Department of Biology and Biochemistry, Faculty of Science, Birzeit University, Birzeit, State of Palestine
3Rafidia Governmental Hospital, Ministry of Health, Nablus, State of Palestine

Correspondence should be addressed to Fekri Samarah; ude.juaa@haramas.irkef

Received 27 February 2018; Revised 2 May 2018; Accepted 9 May 2018; Published 6 June 2018

Academic Editor: Maria Rios

Copyright © 2018 Fekri Samarah et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. Transfusion of red blood cells (RBC) is an essential therapeutic tool in sickle cell disease (SCD). Repeated RBC transfusions can cause alloimmunization which causes difficulty in cross-matching and finding compatible blood for transfusions. This study aimed to investigate the frequency of RBC alloimmunization and related risk factors among Palestinian SCD patients. Materials and Methods. A multicenter cross-sectional study on 116 previously transfused SCD patients from three centers in West Bank, Palestine. Demographic, medical data and history of transfusion were recorded. Blood samples were collected from transfused consenting SCD patients. Gel card method was used for antibody screening and identification. In all patients, autocontrol and direct antiglobulin (DAT) test were performed using polyspecific (anti-IgG + C3d) anti-human globulin (AHG) gel cards for the detection of autoantibodies. Results. Of the SCD patients, 62 (53.4%) patients were HbSS and 54 (46.6%) patients were sickle β-thalassemia (S/β-thal). There were 53 (45.7%) females and 63 (54.3%) males. Mean age was 18.8 years (range 3-53 years). The frequency of RBC alloimmunization among SCD patients was 7.76%, with anti-K showing the highest frequency (33.3%) followed by anti-E (22.2%), anti-D (11.1%), anti-C (11.1%), and anti-c (11.1%). All reported IgG alloantibodies were directed against antigens in the Rh (66.7%) and Kell (33.3%) systems. Older ages of patients, increased number of blood units transfused, and splenectomy were the commonest risk factors for alloimmunization in our study. Conclusions. RBC alloimmunization rate among Palestinian SCD patients is low compared to neighboring countries and countries all over the world but still warrants more attention. Phenotyping of donors/recipients’ RBC for Rh antigens and K1 (partial phenotype matching) before their first transfusion may reduce the incidence of alloimmunization.